Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $32.50.

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Biodesix Trading Up 5.6%

NASDAQ:BDSX opened at $11.45 on Tuesday. The firm has a market capitalization of $91.14 million, a P/E ratio of -2.06 and a beta of 0.66. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. The company has a fifty day moving average of $8.54 and a 200 day moving average of $8.04. Biodesix has a 52 week low of $3.44 and a 52 week high of $20.40.

Insider Activity

In other news, Director Jack W. Schuler bought 20,000 shares of Biodesix stock in a transaction on Monday, January 26th. The shares were purchased at an average price of $11.80 per share, for a total transaction of $236,000.00. Following the acquisition, the director owned 1,563,210 shares of the company’s stock, valued at approximately $18,445,878. The trade was a 1.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Scott Hutton sold 3,559 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the completion of the transaction, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at $457,763.04. This represents a 7.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 7,672 shares valued at $73,576. Company insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Biodesix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BDSX. Aberdeen Group plc purchased a new position in Biodesix during the fourth quarter valued at $1,784,000. XTX Topco Ltd grew its position in shares of Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the period. Monashee Investment Management LLC increased its stake in shares of Biodesix by 12.3% in the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after acquiring an additional 12,348 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares in the last quarter. Finally, State Street Corp lifted its position in Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares during the period. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.